

Preliminary Amendment
Divisional of U.S. Appln No. 09/830,167

REMARKS

The specification, claim 1 and the Abstract have been amended to correct an inadvertent error in formulae (1-1) and (1-2) for Z, wherein X in the formulae has been changed to X'. The basis for the change can be seen in the subsequent disclosure of X' at, e.g., page 7, line 1, and the overall disclosure at, e.g., page 6, line 18 to page 7, line 9 in the application.

New claims 45-53 correspond to original claims 1-32 and 44 amended to meet the limitations of Group IV compounds per the Restriction Requirement issued October 4, 2001 in parent application 09/830,167.

Entry of the above amendment is respectfully requested.

Respectfully submitted,




Susan J. Mack
Registration No. 30,951



SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860
Date:

Preliminary Amendment
Divisional of U.S. Appln No. 09/830,167

Compounds expressed by the following general formula (1),



[wherein, R₀₁ and R₀₂ are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1) to (1-5)].



Preliminary Amendment
Divisional of U.S. Appln No. 09/830,167

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

www.uspto.gov/patent/treatment/allowance.html

